Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?
Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1986 |
|---|
| Umfang: |
6 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Inflammation research - 1969, 18(1986) vom: März/Apr., Seite 288-293 |
| Übergeordnetes Werk: |
volume:18 ; year:1986 ; month:03/04 ; pages:288-293 ; extent:6 |
| Links: |
|---|
| Katalog-ID: |
NLEJ189095954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ189095954 | ||
| 003 | DE-627 | ||
| 005 | 20230506082634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070525s1986 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ189095954 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| 264 | 1 | |c 1986 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Church, Martin K. |4 oth | |
| 773 | 0 | 8 | |i in |t Inflammation research |d 1969 |g 18(1986) vom: März/Apr., Seite 288-293 |w (DE-627)NLEJ188993533 |w (DE-600)1459194-7 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:1986 |g month:03/04 |g pages:288-293 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01964986 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 1986 |c 3/4 |h 288-293 |g 6 | ||
| matchkey_str |
article:1420908X:1986----::sniiinfateleitreesrlvnttelnclci |
|---|---|
| hierarchy_sort_str |
1986 |
| publishDate |
1986 |
| allfields |
(DE-627)NLEJ189095954 DE-627 ger DE-627 rakwb eng Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? 1986 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. Springer Online Journal Archives 1860-2002 Church, Martin K. oth in Inflammation research 1969 18(1986) vom: März/Apr., Seite 288-293 (DE-627)NLEJ188993533 (DE-600)1459194-7 1420-908X nnns volume:18 year:1986 month:03/04 pages:288-293 extent:6 http://dx.doi.org/10.1007/BF01964986 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 18 1986 3/4 288-293 6 |
| spelling |
(DE-627)NLEJ189095954 DE-627 ger DE-627 rakwb eng Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? 1986 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. Springer Online Journal Archives 1860-2002 Church, Martin K. oth in Inflammation research 1969 18(1986) vom: März/Apr., Seite 288-293 (DE-627)NLEJ188993533 (DE-600)1459194-7 1420-908X nnns volume:18 year:1986 month:03/04 pages:288-293 extent:6 http://dx.doi.org/10.1007/BF01964986 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 18 1986 3/4 288-293 6 |
| allfields_unstemmed |
(DE-627)NLEJ189095954 DE-627 ger DE-627 rakwb eng Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? 1986 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. Springer Online Journal Archives 1860-2002 Church, Martin K. oth in Inflammation research 1969 18(1986) vom: März/Apr., Seite 288-293 (DE-627)NLEJ188993533 (DE-600)1459194-7 1420-908X nnns volume:18 year:1986 month:03/04 pages:288-293 extent:6 http://dx.doi.org/10.1007/BF01964986 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 18 1986 3/4 288-293 6 |
| allfieldsGer |
(DE-627)NLEJ189095954 DE-627 ger DE-627 rakwb eng Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? 1986 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. Springer Online Journal Archives 1860-2002 Church, Martin K. oth in Inflammation research 1969 18(1986) vom: März/Apr., Seite 288-293 (DE-627)NLEJ188993533 (DE-600)1459194-7 1420-908X nnns volume:18 year:1986 month:03/04 pages:288-293 extent:6 http://dx.doi.org/10.1007/BF01964986 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 18 1986 3/4 288-293 6 |
| allfieldsSound |
(DE-627)NLEJ189095954 DE-627 ger DE-627 rakwb eng Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? 1986 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. Springer Online Journal Archives 1860-2002 Church, Martin K. oth in Inflammation research 1969 18(1986) vom: März/Apr., Seite 288-293 (DE-627)NLEJ188993533 (DE-600)1459194-7 1420-908X nnns volume:18 year:1986 month:03/04 pages:288-293 extent:6 http://dx.doi.org/10.1007/BF01964986 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 18 1986 3/4 288-293 6 |
| language |
English |
| source |
in Inflammation research 18(1986) vom: März/Apr., Seite 288-293 volume:18 year:1986 month:03/04 pages:288-293 extent:6 |
| sourceStr |
in Inflammation research 18(1986) vom: März/Apr., Seite 288-293 volume:18 year:1986 month:03/04 pages:288-293 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Inflammation research |
| authorswithroles_txt_mv |
Church, Martin K. @@oth@@ |
| publishDateDaySort_date |
1986-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188993533 |
| id |
NLEJ189095954 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ189095954</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082634.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070525s1986 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ189095954</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1986</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Church, Martin K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Inflammation research</subfield><subfield code="d">1969</subfield><subfield code="g">18(1986) vom: März/Apr., Seite 288-293</subfield><subfield code="w">(DE-627)NLEJ188993533</subfield><subfield code="w">(DE-600)1459194-7</subfield><subfield code="x">1420-908X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:1986</subfield><subfield code="g">month:03/04</subfield><subfield code="g">pages:288-293</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01964986</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">1986</subfield><subfield code="c">3/4</subfield><subfield code="h">288-293</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188993533 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1420-908X |
| topic_title |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m k c mk mkc |
| hierarchy_parent_title |
Inflammation research |
| hierarchy_parent_id |
NLEJ188993533 |
| hierarchy_top_title |
Inflammation research |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188993533 (DE-600)1459194-7 |
| title |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| spellingShingle |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| ctrlnum |
(DE-627)NLEJ189095954 |
| title_full |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| journal |
Inflammation research |
| journalStr |
Inflammation research |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1986 |
| contenttype_str_mv |
zzz |
| container_start_page |
288 |
| container_volume |
18 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| title_sort |
is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| title_auth |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| abstract |
Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. |
| abstractGer |
Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. |
| abstract_unstemmed |
Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs? |
| url |
http://dx.doi.org/10.1007/BF01964986 |
| remote_bool |
true |
| author2 |
Church, Martin K. |
| author2Str |
Church, Martin K. |
| ppnlink |
NLEJ188993533 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| up_date |
2024-07-06T00:00:10.424Z |
| _version_ |
1803785611957501952 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ189095954</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082634.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070525s1986 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ189095954</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is inhibition of mast cell mediator release relevant to the clinical activity of anti-allergic drugs?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1986</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conclusions The introduction of SCG for the treatment of bronchial asthma was viewed by many as the advent of a new era, the era of the antiallergic drug which acted by suppressing the release of inflammatory mediators from mast cells. However, some 17 years on, SCG is the only drug of its type on the market. Efforts to improve its efficacy by chemical modification have not succeeded. As it is now clear that all of the beneficial effects of SCG in asthma cannot be attributed to its effects on mast cell mediator secretion, it is not surprising that mast cell models are not predictive of clinical activity. Perhaps a clearer understanding of the basic bio-chemical mechanisms of SCG and its actions in animals and man may lead to development of more relevant models and to a more potent drug.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Church, Martin K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Inflammation research</subfield><subfield code="d">1969</subfield><subfield code="g">18(1986) vom: März/Apr., Seite 288-293</subfield><subfield code="w">(DE-627)NLEJ188993533</subfield><subfield code="w">(DE-600)1459194-7</subfield><subfield code="x">1420-908X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:18</subfield><subfield code="g">year:1986</subfield><subfield code="g">month:03/04</subfield><subfield code="g">pages:288-293</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01964986</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">18</subfield><subfield code="j">1986</subfield><subfield code="c">3/4</subfield><subfield code="h">288-293</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.399373 |